Peter Chambré

Peter has been Chair of Cancer Research Horizons (formerly Cancer Research Technology) since October 2011. He has also been a Trustee of Cancer Research UK since 2016.

Peter is on the board of Our Future Health and is Chair of Immatics N.V., a company developing new cancer immunotherapy treatments, which is listed on Nasdaq. He has been a director of a number of public and private healthcare and life science companies, and was Chief Executive Officer of Cambridge Antibody Technology plc from 2002 until its acquisition by AstraZeneca in 2006.